JP6679309B2 - 自閉症スペクトラム障害の診断および処置 - Google Patents

自閉症スペクトラム障害の診断および処置 Download PDF

Info

Publication number
JP6679309B2
JP6679309B2 JP2015530008A JP2015530008A JP6679309B2 JP 6679309 B2 JP6679309 B2 JP 6679309B2 JP 2015530008 A JP2015530008 A JP 2015530008A JP 2015530008 A JP2015530008 A JP 2015530008A JP 6679309 B2 JP6679309 B2 JP 6679309B2
Authority
JP
Japan
Prior art keywords
subject
asd
treatment
composition
4eps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015530008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529668A5 (enExample
JP2015529668A (ja
Inventor
シャオ イレイン
シャオ イレイン
ケイ マズマニアン サーキス
ケイ マズマニアン サーキス
エイチ パターソン ポール
エイチ パターソン ポール
マックブライド サラ
マックブライド サラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Institute of Technology
Original Assignee
California Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute of Technology filed Critical California Institute of Technology
Publication of JP2015529668A publication Critical patent/JP2015529668A/ja
Publication of JP2015529668A5 publication Critical patent/JP2015529668A5/ja
Application granted granted Critical
Publication of JP6679309B2 publication Critical patent/JP6679309B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7057—(Intracellular) signaling and trafficking pathways
    • G01N2800/7066—Metabolic pathways
    • G01N2800/7076—Amino acid metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7057—(Intracellular) signaling and trafficking pathways
    • G01N2800/7066—Metabolic pathways
    • G01N2800/7085—Lipogenesis or lipolysis, e.g. fatty acid metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
JP2015530008A 2012-08-29 2013-08-28 自閉症スペクトラム障害の診断および処置 Active JP6679309B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261694679P 2012-08-29 2012-08-29
US61/694,679 2012-08-29
PCT/US2013/057148 WO2014036182A2 (en) 2012-08-29 2013-08-28 Diagnosis and treatment of autism spectrum disorder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018168982A Division JP2019031497A (ja) 2012-08-29 2018-09-10 自閉症スペクトラム障害の診断および処置

Publications (3)

Publication Number Publication Date
JP2015529668A JP2015529668A (ja) 2015-10-08
JP2015529668A5 JP2015529668A5 (enExample) 2016-10-20
JP6679309B2 true JP6679309B2 (ja) 2020-04-15

Family

ID=50184623

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015530008A Active JP6679309B2 (ja) 2012-08-29 2013-08-28 自閉症スペクトラム障害の診断および処置
JP2018168982A Pending JP2019031497A (ja) 2012-08-29 2018-09-10 自閉症スペクトラム障害の診断および処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018168982A Pending JP2019031497A (ja) 2012-08-29 2018-09-10 自閉症スペクトラム障害の診断および処置

Country Status (7)

Country Link
US (2) US10220089B2 (enExample)
EP (1) EP2890808A4 (enExample)
JP (2) JP6679309B2 (enExample)
CN (2) CN114949001A (enExample)
AU (2) AU2013308826B2 (enExample)
CA (1) CA2881656C (enExample)
WO (1) WO2014036182A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019031497A (ja) * 2012-08-29 2019-02-28 カリフォルニア インスティチュート オブ テクノロジー 自閉症スペクトラム障害の診断および処置

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
BR112013002667B1 (pt) 2010-08-04 2020-02-04 Thomas Julius Borody composições para transplante da flora intestinal e métodos para fazê-las e usá-las e dispositivos para administrá-las
EP3610881A1 (en) 2011-03-09 2020-02-19 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
MX2016000293A (es) * 2013-07-09 2016-06-21 Stemina Biomarker Discovery Inc Biomarcadores del trastrono del espectro autista.
US9176113B1 (en) * 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
EP3209803A4 (en) 2014-10-21 2018-06-13 Ubiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
HK1244461A1 (zh) * 2014-10-30 2018-08-10 加利福尼亚技术学院 用於改善神经发育障碍中的行为的包含细菌的组合物和方法
WO2016069792A1 (en) * 2014-10-30 2016-05-06 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
EP3212207A4 (en) 2014-10-30 2018-06-13 California Institute of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
EP3193901B1 (en) 2014-12-23 2018-04-04 4D Pharma Research Limited Pirin polypeptide and immune modulation
ES2658310T3 (es) 2014-12-23 2018-03-09 4D Pharma Research Limited Una cepa de bacteroides thetaiotaomicron y su uso en la reducción de la inflamación
JP6611156B2 (ja) * 2015-01-30 2019-11-27 史郎 栃谷 妊娠期母体腸内細菌攪乱による行動異常モデル動物の作製方法とその用途
US10525020B2 (en) 2015-02-11 2020-01-07 Laboratory Corporation Of America Holdings Metabolic markers of attention deficit hyperactivity disorder
EP3268354B1 (en) 2015-03-13 2020-05-06 Mironova Innovations, LLC Nalpha, nalpha, nalpha-trialkyl histidine derivatives useful for the preparation of ergothioneine compounds
EP3283086A4 (en) * 2015-04-13 2019-04-24 Ubiome Inc. METHOD AND SYSTEM FOR MICROBIOMY-DERIVED DIAGNOSTICS AND THERAPEUTIC FOR DISEASES RELATED TO MICROBIOMIC FUNCTIONAL PROPERTIES
AU2016248050A1 (en) * 2015-04-13 2017-11-09 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
AU2016250102A1 (en) * 2015-04-13 2017-11-09 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
CN107949391B (zh) 2015-05-14 2021-11-09 克雷斯顿沃控股公司 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置
PT3297644T (pt) * 2015-05-22 2022-03-30 Univ Arizona State Métodos para tratar distúrbios do espetro do autismo e sintomas associados
TWI759266B (zh) 2015-06-15 2022-04-01 英商4D製藥研究有限公司 包含細菌菌株之組合物之用途
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA55434B1 (fr) 2015-06-15 2022-02-28 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PT3307288T (pt) 2015-06-15 2019-10-17 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
CN105213433A (zh) * 2015-11-06 2016-01-06 王益超 一种用于治疗孤独症、复发性流产和不孕症的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA45287A (fr) 2015-11-20 2018-08-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN105543369B (zh) * 2016-01-13 2020-07-14 金锋 精神障碍的生物标志物及其应用
PT3313423T (pt) 2016-03-04 2019-07-10 4D Pharma Plc Composições que compreendem a estirpe blautia bacteriana para tratar a hipersensibilidade visceral
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
WO2017197252A1 (en) * 2016-05-13 2017-11-16 Stemina Biomarker Discovery, Inc. Autism subsets
WO2017205302A1 (en) 2016-05-23 2017-11-30 California Institute Of Technology Regulate gut microbiota to treat neurodegenerative disorders
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
MX2019002918A (es) 2016-09-16 2019-07-18 Dyax Corp Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018089794A1 (en) * 2016-11-11 2018-05-17 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for changing metabolite levels in a subject
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
BR112018076609B1 (pt) * 2016-12-15 2023-02-14 Société des Produits Nestlé S.A. Composição alimentícia para animais de estimação, seus usos, e métodos não terapêutico para modular a quantidade e para medição de uma alteração na quantidade de pelo menos uma dentre bifidobacterium, lactobacillus ou clostridium perfringens
EP3579924A4 (en) * 2017-02-07 2020-12-23 California Institute of Technology MODULATION OF THE INTESTINAL MICROBIOTE IN HUNTINGTON'S DISEASE AND RETT SYNDROME
JP7324709B2 (ja) * 2017-02-09 2023-08-10 コグノア，インク． デジタル個別化医療のためのプラットフォームとシステム
WO2018152133A1 (en) * 2017-02-14 2018-08-23 California Institute Of Technology Modulation of microbial synthesis of 4-etylphenol and 4-ethylphenol sulfate in behavior and disease
EP3600349A4 (en) * 2017-03-31 2020-09-30 Axial Biotherapeutics, Inc. SELECTIVE GUT SEQUESTRATION AGENTS FOR THE TREATMENT AND PREVENTION OF AUTISM AND RELATED DISORDERS
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
WO2018187467A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating parkinson's disease (pd) and related disorders
WO2018213204A1 (en) 2017-05-15 2018-11-22 Axial Biotherapeutics, Inc. Inhibitors of microbially induced amyloid
RS61872B1 (sr) 2017-05-22 2021-06-30 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
WO2018216912A1 (ko) * 2017-05-26 2018-11-29 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 자폐증 진단방법
WO2018218159A1 (en) 2017-05-26 2018-11-29 Crestovo Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
JP6840272B2 (ja) 2017-06-14 2021-03-10 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
EP3638271B1 (en) 2017-06-14 2020-10-14 4D Pharma Research Limited Compositions comprising bacterial strains
RS63393B1 (sr) 2017-06-14 2022-08-31 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
US11883155B2 (en) 2017-07-05 2024-01-30 Yusuf Ozgur Cakmak System for monitoring auditory startle response
US11141089B2 (en) * 2017-07-05 2021-10-12 Yusuf Ozgur Cakmak System for monitoring auditory startle response
US10939862B2 (en) * 2017-07-05 2021-03-09 Yusuf Ozgur Cakmak System for monitoring auditory startle response
AU2018253466B2 (en) 2017-07-17 2019-03-28 smartDNA Pty Ltd Method of diagnosing a dysbiosis
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
US20230158084A1 (en) * 2018-01-05 2023-05-25 California Institute Of Technology Probiotics, metabolites, and uses thereof
WO2019180263A2 (en) 2018-03-22 2019-09-26 Adare Pharmaceuticals Sas New use of microbiological compositions
WO2020012467A2 (en) * 2018-07-08 2020-01-16 Yeda Research And Development Co. Ltd. Person-specific assessment of probiotics responsiveness
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CN109142744A (zh) * 2018-07-26 2019-01-04 珠海中科先进技术研究院有限公司 一种自闭症谱系障碍诊断试剂盒
CN113164527A (zh) 2018-09-27 2021-07-23 芬奇治疗控股有限责任公司 用于治疗癫痫和相关障碍的组合物和方法
CA3118790A1 (en) 2018-11-06 2020-05-14 Stalicla Sa Metabolic profiling for the diagnosis of a subset of idiopathic autism spectrum disorder patients, asd phenotype 1
US11676719B2 (en) * 2018-12-20 2023-06-13 Oregon Health & Science University Subtyping heterogeneous disorders using functional random forest models
CN109706235A (zh) * 2019-01-29 2019-05-03 广州康昕瑞基因健康科技有限公司 一种肠道微生物菌群的检测和分析方法及其系统
CA3136303A1 (en) 2019-04-05 2020-10-08 Arizona Board Of Regents On Behalf Of Arizona State University Diagnostic for childhood risk of autism spectrum disorder
WO2020206443A1 (en) * 2019-04-05 2020-10-08 Arizona Board Of Regents On Behalf Of Arizona State University Metabolites as diagnostics for autism spectrum disorder in children with gastrointestinal symptoms
US20220373563A1 (en) * 2019-04-23 2022-11-24 Peking Union Medical College Hospital Machine learning-based autism spectrum disorder diagnosis method and device using metabolite as marker
EP3965820A4 (en) 2019-05-07 2023-02-08 The Regents of the University of California COMPOSITIONS AND METHODS TO PROMOTE HEALTHY NEURAL DEVELOPMENT IN AN UNBORN BABY
CN110178787B (zh) * 2019-05-08 2022-03-22 河南中医药大学 一种运用粪菌移植法建立自闭症大鼠模型的方法
PE20221399A1 (es) 2019-07-19 2022-09-15 Finch Therapeutics Holdings Llc Metodos y productos para el tratamiento de trastornos gastrointestinales
EP4041265A4 (en) * 2019-10-11 2024-03-27 Stemina Biomarker Discovery, Inc. DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDERS ASSOCIATED WITH ALTERED LEVELS OF METABOLITES CONCENTRATIONS
TWI870485B (zh) 2019-10-21 2025-01-21 日商表飛鳴製藥股份有限公司 多形類桿菌６０３０之用途
US20230026402A1 (en) * 2019-10-22 2023-01-26 Cornell University Microbiota based therapies to promote mental health
WO2021126220A1 (en) * 2019-12-19 2021-06-24 Hill's Pet Nutrition, Inc. Compositions and methods of treating and reducing risk of conditions associated with elevated 4-ethylphenyl sulfate in canines using tomato pomace and methods of identifying canines at risk of such conditions
US20230145281A1 (en) * 2020-03-06 2023-05-11 University Of Virginia Patent Foundation System and method for predicting risk of diagnosis for autism spectrum disorder using neonatal analytics
CN111455076B (zh) * 2020-04-17 2022-10-21 济南市儿童医院 用于儿童孤独症评估的口腔菌群微生物
CN116547520A (zh) * 2020-09-21 2023-08-04 分子优公司 孤独症谱系障碍的诊断与治疗方法
KR20230074216A (ko) * 2020-09-21 2023-05-26 몰레큘러 유 코포레이션 자폐 스펙트럼 장애의 진단 및 치료 방법
CN117083062A (zh) * 2020-10-19 2023-11-17 第二基因组公司 用于治疗孤独症谱系障碍的方法
CN114544826B (zh) * 2020-11-24 2023-12-08 重庆医科大学 检测血浆中组氨酸的试剂在制备抑郁症检测试剂盒中的用途
EP4012414A1 (en) 2020-12-11 2022-06-15 Stalicla S.A. Diagnosis of autism spectrum disorder phenotype 1
CN113069469B (zh) * 2021-04-07 2022-12-13 上海市精神卫生中心（上海市心理咨询培训中心） 调节性t细胞在制备治疗孤独症药物或细胞疗法中的应用
CN114699423B (zh) * 2022-02-16 2023-06-23 广州知易生物科技有限公司 脆弱拟杆菌的荚膜多糖提取物在制备防治精神分裂症的药物中的应用
CN114699424B (zh) * 2022-02-16 2023-07-18 广州知易生物科技有限公司 脆弱拟杆菌两性离子荚膜多糖或/和改性的两性离子荚膜多糖的新应用
CN114457153A (zh) * 2022-03-15 2022-05-10 西安交通大学 一种孤独症血清神经元来源外泌体标志物chrm1的应用
CN117598247A (zh) * 2022-03-25 2024-02-27 天津中医药大学 咪唑丙酸在制备用于诱导溃疡性结肠炎动物模型的造模剂中的应用
CN114622026B (zh) * 2022-04-02 2024-10-01 中南大学湘雅三医院 拟杆菌作为预测自闭症疗效的客观指标
CN116990395A (zh) * 2022-04-26 2023-11-03 中国科学院深圳先进技术研究院 一种基于粪便的阿尔兹海默症生物标志物及其应用
CN115368300B (zh) * 2022-10-27 2023-03-24 北京拓领博泰生物科技有限公司 用于tlr8抑制剂的化合物及其制备方法、应用
CN115616227B (zh) * 2022-11-18 2023-05-16 四川大学华西医院 吲哚-3-丙烯酰甘氨酸检测试剂的用途、诊断或辅助诊断慢性阻塞性肺病的试剂盒及系统
US12005044B1 (en) 2022-11-29 2024-06-11 Autism Therapeutics Inc. Treatment of autism spectrum disorders with ergothioneine, selenoneine, or combinations thereof
WO2025007066A1 (en) * 2023-06-30 2025-01-02 University Of Massachusetts Biomarkers and methods related to fragile x syndrome

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
US5951977A (en) 1997-10-14 1999-09-14 The United States Of America, As Represented By The Secretary Of Agriculture Competitive exclusion culture for swine
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20040005304A1 (en) 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7749509B2 (en) 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US20060177424A1 (en) 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
CA2586334A1 (en) 2004-11-16 2006-06-08 Neurochem (International) Limited Compounds for the treatment of cns and amyloid associated diseases
GB0504096D0 (en) 2005-02-28 2005-04-06 Tipogen As Method
US20100233312A9 (en) 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
ES2473625T3 (es) 2007-10-26 2014-07-07 Brenda E. Moore Composición probi�tica y métodos para inducir y mantener la pérdida de peso
DK2220030T3 (en) 2007-11-06 2016-04-11 Edison Pharmaceuticals Inc 4- (P-QUINONYL) -2-HYDROXYBUTANAMIDDERIVATER TO TREAT mitochondrial
CA2711608A1 (en) 2008-01-09 2009-07-16 Yale University Mutations in contaction associated protein 2 (cntnap2) are associated with increased risk for ideopathic autism
EP2358370A2 (en) 2008-11-13 2011-08-24 Link Medicine Corporation Treatment of proteinopathies using a farnesyl transferase inhibitor
WO2010111516A2 (en) 2009-03-25 2010-09-30 Whitehead Institute For Biomedical Research Compositions and methods for inhibiting biofilms
US9050276B2 (en) * 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
US20110081320A1 (en) * 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
JP2013507394A (ja) 2009-10-09 2013-03-04 プロセラ インコーポレイテッド 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法
CA2797787C (en) * 2010-04-29 2019-07-09 Wisconsin Alumni Research Foundation Metabolic biomarkers of autism
US9707207B2 (en) 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
WO2011153226A2 (en) 2010-06-01 2011-12-08 Moore Research Enterprises Llc Cellular constituents from bacteroides, compositions thereof, and therapeutic methods employing bacteroides or cellular constituents thereof
US20130115257A1 (en) 2010-07-08 2013-05-09 Katholieke Universiteit Leuven Compositions and methods for removal or destruction of amyloid fibril or amyloid adhesin comprising aggregates
JP5931884B2 (ja) * 2010-10-07 2016-06-08 カリフォルニア インスティチュート オブ テクノロジー 自閉症の生菌療法
US20120237482A1 (en) 2011-03-18 2012-09-20 Juan Rodriguez Methods for treatment of neurological disorders by modulation of microglial activation
EP3569690B1 (en) 2011-12-01 2024-08-28 The University of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
US20150265661A1 (en) 2012-04-13 2015-09-24 Trustees Of Boston College Prebiotic effect of sialyllactose
US10220089B2 (en) * 2012-08-29 2019-03-05 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
KR102222273B1 (ko) 2013-02-04 2021-03-08 세레스 테라퓨틱스, 인코포레이티드 조성물 및 방법
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
FI127671B (en) 2014-05-28 2018-11-30 Filip Scheperjans Method for diagnostics of Parkinson’s disease
CN104546932A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 卵形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
HK1244461A1 (zh) 2014-10-30 2018-08-10 加利福尼亚技术学院 用於改善神经发育障碍中的行为的包含细菌的组合物和方法
EP3212207A4 (en) 2014-10-30 2018-06-13 California Institute of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
WO2016069792A1 (en) 2014-10-30 2016-05-06 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
US20170360853A1 (en) 2015-01-07 2017-12-21 Ecole Polytechnique Federale De Lausanne (Epfl) Gastro-Intestinal Biomarkers for Diagnosis and Therapies of Proteinopathies
PT3297644T (pt) 2015-05-22 2022-03-30 Univ Arizona State Métodos para tratar distúrbios do espetro do autismo e sintomas associados
WO2017205302A1 (en) 2016-05-23 2017-11-30 California Institute Of Technology Regulate gut microbiota to treat neurodegenerative disorders
US11324717B2 (en) 2016-06-22 2022-05-10 Microbial Research Management Health Nv Microbial carotenoids affecting gut microbial composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019031497A (ja) * 2012-08-29 2019-02-28 カリフォルニア インスティチュート オブ テクノロジー 自閉症スペクトラム障害の診断および処置

Also Published As

Publication number Publication date
AU2019206081A1 (en) 2019-08-08
AU2019206081B2 (en) 2021-06-10
CA2881656C (en) 2023-07-11
AU2013308826B2 (en) 2019-04-18
CN104768560A (zh) 2015-07-08
US11052151B2 (en) 2021-07-06
EP2890808A2 (en) 2015-07-08
AU2013308826A1 (en) 2015-02-26
EP2890808A4 (en) 2016-09-28
CA2881656A1 (en) 2014-03-06
JP2019031497A (ja) 2019-02-28
US10220089B2 (en) 2019-03-05
US20190231871A1 (en) 2019-08-01
WO2014036182A2 (en) 2014-03-06
WO2014036182A3 (en) 2014-05-01
CN114949001A (zh) 2022-08-30
JP2015529668A (ja) 2015-10-08
US20140065132A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
JP6679309B2 (ja) 自閉症スペクトラム障害の診断および処置
Kim et al. Antibiotics-induced dysbiosis of intestinal microbiota aggravates atopic dermatitis in mice by altered short-chain fatty acids
Bhattacharjee et al. Environmental enteric dysfunction induces regulatory T cells that inhibit local CD4+ T cell responses and impair oral vaccine efficacy
AU2015339284B2 (en) Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
Berni Canani et al. Skin, gut, and lung barrier: physiological interface and target of intervention for preventing and treating allergic diseases
Gu et al. Fusobacterium nucleatum causes microbial dysbiosis and exacerbates visceral hypersensitivity in a colonization-independent manner
JP2018502056A (ja) 神経発達症群における行動の改善のための細菌含有組成物、及び細菌を使用することを含む、神経発達症群における行動の改善のための方法
Li et al. Congenitally underdeveloped intestine drives autism-related gut microbiota and behavior
JPWO2018084172A1 (ja) Ｔｈ１細胞を誘導する細菌
US20240226191A1 (en) Compositions and methods for treating disease
Miranda-Ribera et al. The Zonulin-transgenic mouse displays behavioral alterations ameliorated via depletion of the gut microbiota
Wei et al. Alzheimer’s Disease-Derived outer membrane vesicles exacerbate cognitive dysfunction, modulate the gut microbiome, and increase neuroinflammation and Amyloid-β production
Hamade et al. BATF3 protects against metabolic syndrome and maintains intestinal epithelial homeostasis
HK40079872A (en) Diagnosis and treatment of autism spectrum disorder
CA3238009A1 (en) Bacterial strains for treating disease
Lebovitz Modulation of Neurodevelopmental Outcomes using Lactobacillus in a Model of Maternal Microbiome Dysbiosis
Gogoi Neuroprotective Effect of Gut Microbiota Modulation in Alzheimer's Disease: a Preclinical Study
Latham Infectious Disease, Age, and Environmental Contaminants As Neurotoxicants That Modulate Glia and Contribute to Neurodegenerative Pathology
Lehman Effect of gut microbiota modulation during early-life and adulthood on host immunity
Cox The Aged Microbiome Drives Cognitive Decline
Kim HaJung et al. Antibiotics-induced dysbiosis of intestinal microbiota aggravates atopic dermatitis in mice by altered short-chain fatty acids.
Yahfoufi Role of a Novel Probiotic in Immune Homeostasis, Microbiome and MicroRNAs' Modulation at the Gut and Brain Levels
Yang et al. Prenatal Poly I: C exposure affects tryptophan-kynurenine metabolism associated with intestinal microbiome in female juvenile rats
Beebe Investigating the Microbe-Specific Effects in Multiple Sclerosis and CNS Autoimmunity
Perez Guzman Functional Relationship Between Gut Microbiota and Anxiety

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180910

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180920

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20181130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191211

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200318

R150 Certificate of patent or registration of utility model

Ref document number: 6679309

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250